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The objectives of this study were to determine the toxicity of intratumoural/intrapleural SRL172 in addition to intradermal
SRL172 and standard chemotherapy (mitomycin-C, vinblastine and cisplatin) in patients with malignant mesothelioma. Patients
received chemotherapy (mitomycin-C: 8 mg m
72, vinblastine: 6 mg m
72, cisplatin 50 mg m
72) on a 3-weekly basis for up to
six courses. IP SRL172 injections were given 3-weekly prior to chemotherapy and escalated in groups of three patients from
1 mg to 1 mg bacilli in 10-fold increments. Patients were also given ID SRL172 at a dose of 1 mg bacilli 4-weekly. Patients
were assessed for toxicity after each course of chemotherapy and for response by CT imaging. Immuno-haematological
parameters were analyzed pre-treatment and 1 month after completion of treatment. There was no dose limiting toxicity with
IP SRL172 although there was greater toxicity at the highest dose (n=13). There were six out of 16 partial responses (37.5%).
Haemato-immunological parameters, measured in seven patients pre and post-therapy, revealed that response rate correlated
with a decrease in platelet count and there was an increase in activation of natural killer cells and a decrease in the percentage
of IL-4 producing T cells in all tested patients post-treatment. SRL172 can be given safely into tumour deposits and the pleural
cavity in patients with malignant mesothelioma and we have established the dose for phase II testing.
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The incidence of mesothelioma is rising, from around 1000 cases per
year in the UK at present, to a predicted peak of nearly 3000 by the
year 2020, i.e. 1% of all male deaths (Peto et al, 1995). This increase
is due to asbestos exposure which continued into the late 1960s. The
median survival from the time of diagnosis is 4–18 months with 5%
of patients alive at 5 years. The factors which predict for poor
outcome are male sex, performance status, non epithelial pathology,
low haemoglobin, high white cell count and high platelet count
(Curran et al, 1998; Herndon et al, 1998; Edwards et al, 2000). No
single treatment modality appears to make a signiﬁcant difference
to the outcome of this disease (Ong and Vogelzang, 1996). There is
therefore a great need for improved treatment in mesothelioma.
Currently we use a combination chemotherapy, mitomycin, cisplatin
and vinblastine (MVP), which has been shown to lead to sympto-
matic control and acceptable toxicity in patients with malignant
mesothelioma (Middleton et al, 1998). With this chemotherapy regi-
men, we expect objective response rates of around 20%.
SRL172 is a suspension of heat-killed Mycobacterium vaccae, a
fast growing avirulent mycobacterium, that may have non-speciﬁc
immunomodulating properties, e.g. it may promote Th1 and down
regulate Th2 cytokine production (Grange et al, 1995). The
proposed rationale behind the combination was that the
chemotherapy, although slightly immunosuppressive, could cause
the in vivo release and subsequent presentation of tumour antigens
and trigger a tumour speciﬁc response by the immune system when
boosted by an immuno-modulator like SRL172. Previously we have
investigated the role of intradermal SRL172 (4-weekly) in combina-
tion with MVP chemotherapy (3-weekly) in a randomized phase II
trial of 28 symptomatic patients with non-small cell lung cancer
(NSCLC) and mesothelioma. There was a trend towards improved
response rate (54% vs 33%), improved median survival (9.7
months vs 7.5 months) and improved 1 year survival (42% vs
18%) in patients who received both chemotherapy and SRL172
compared to those in the chemotherapy alone group. When the
data were analyzed separately for NSCLC and for mesothelioma,
the potential beneﬁt of the combination was seen in both cancers
(O’Brien et al, 2000). We have also reported similar results in
SCLC (Assersohn et al, 2002).
In this study, intrapleural/intratumoural SRL172 injections were
added to intradermal SRL172 and chemotherapy in patients with
malignant mesothelioma. The rationale behind this new study
was that SRL172 in the tumour or in the pleural cavity could result
in an increased concentration of the immunologically active
compound in the vicinity of the tumour, thus causing an inﬂam-
matory reaction which could potentiate the anti-tumour killing
at the tumour site. Indeed, it has been reported that the local
tumour environment of malignant mesothelioma is immunologi-
cally suppressive, due to the secretion of cytokines such as
TGF-b (Fitzpatrick et al, 1995; Marzo et al, 1997). Therefore chan-
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www.bjcancer.comging this local immuno-suppressive environment to a more immu-
no-stimulating environment may be beneﬁcial. SRL172 had not
been administered previously in the pleural cavity, and thus we
initiated a phase I/II clinical trial to document the safety and clin-
ical efﬁcacy of repeated injections of intratumoral/intrapleural
SRL172 in patients, with doses ranging from 1 mg to 1 mg of M.
vaccae bacilli.
PATIENTS AND METHODS
Selection of patients
Intrapleural (IP) and intradermal (ID) SRL172 and chemotherapy
were offered to symptomatic patients of performance status 2
and above with either a histological or cytological diagnosis of
mesothelioma. Patients were recruited in four cohorts correspond-
ing to increasing doses of IP SRL172. Baseline scans were analyzed
and a site for a single IP SRL172 injection was chosen aiming for
the greatest area of bulk noting the proximity of vital structures
and depth of the chest wall at that point. If the disease was compli-
cated by a large pleural effusion, this was drained prior to insertion
of SRL172 into the cavity.
SRL172 suspension
SRL172 was formulated as a suspension of 10 mg ml
71 heat-killed
(autoclaved at 1218C for 15 min) Mycobacterium vaccae in borate
buffered saline (pH 8) and was provided in 3 ml glass vials at a
concentration of 10
9 bacilli per 0.1 ml dose (1 mg) and stored
refrigerated in the dark at 48C in the hospital pharmacy until use.
Treatment schedule
All patients received 3-weekly chemotherapy consisting of mito-
mycin-C (8 mg m
72, omitted courses 3 and 5), vinblastine
6m gm
72 (maximum 10 mg) and cisplatin 50 mg m
72. All
patients also received an intradermal injection of SRL172 (1 mg
bacilli) 4-weekly, starting at the same time as the chemotherapy.
SRL172 IP injections were given 3-weekly. The IP dose of
SRL172 increased tenfold with each cohort vaccine starting at
1 mg bacilli (cohort 1), to 1 mg bacilli in the last cohort (cohort
4). The ﬁrst IP SRL172 injection was given into the site of bulkiest
disease or into the pleural cavity, at the same time as the ﬁrst
chemotherapy and the ﬁrst intradermal injection of SRL172. Only
when two patients had safely received the SRL172 for two courses
could the next cohort commence treatment. Dexamethasone was
omitted as an antiemetic during the ﬁrst course of chemotherapy.
Assessment of toxicity, objective and symptomatic response
Toxicity was assessed after each cycle of chemotherapy using CTC
toxicity grading. Symptomatic responses and objective responses by
means of chest X-ray, haematological and non-haematological toxi-
city were recorded 3-weekly. CT scans were repeated after three
courses of chemotherapy and at the end of treatment.
Clinical outcome was deﬁned as partial response (PR), minor
response (MR), no change (NC) and progressive disease (PD).
Partial response was deﬁned as a decrease of 50% or more in
the product of two diameters which is maintained for at least 1
month according to WHO criteria, a minor response was 25–
49% shrinkage, and progressive disease was a 25% increase. The
responses were also re-evaluated using the RECIST criteria (Ther-
asse et al, 2000) at the end of the study which did not result in
a change of response assessment.
Symptomatic response was deﬁned as complete response (SCR)
if the symptom disappeared, partial response (SPR) if the symptom
improved, no change (SNC) and progressive disease (SPD) if the
symptom did not change or became worse respectively.
Immunological assays
Seven patients had blood taken at baseline and a repeat blood was
taken 1 month after the end of treatment for immunological
studies. As part of the protocol, for each patient, baseline blood
was also taken from the spouse and from an age-sex-matched
control. Paired blood samples were not taken in nine patients
because they had either received prior chemotherapy, they refused
to have blood taken for the immunological study, there was no
suitable available control(s) at the time or they died before the
end of the treatment. All assays were performed with whole blood
requiring only 3.5 ml of blood per patient. Full blood count and
differential counts were performed in a Coulter STKS machine in
the Department of Haematology. Three colour Facscan analysis
of lymphocytes markers were performed as described (Bromelow
et al, 1998) and covered both T cell and NK markers. Mitogenic
lymphocyte stimulations with PHA (10 mgm l
71, Murex),
Pokeweed mitogen (10 mgm l
71, Sigma, Poole, UK) and SEB
(10 mgm l
71, Sigma) were performed with 20 ml of blood diluted
1/10 RPMI1640 after 3 days incubation. Recall antigen stimulations
with tetanus toxoid (5 mgm l
71, Connaught), Inﬂuenza virus (X31,
100 HAU ml
71, gift from Dr Brian Thomas, NIMR, Mill Hill,
UK), tuberculin, (T147S strain, 5 mgm l
71, kind gift of Prof John
Stanford, UCL, London, UK), Mycobacterium vaccae (25 mgm l
71,
gift from J Stanford) and Mycobacterium ﬂavescin (5 mgm l
71, gift
from J Stanford) were performed in the same way as the mitogenic
stimulations but with 5 days incubation. Optimum concentration
for the mitogens, the recall antigens and the allogeneic stimulators
had previously been determined in a pilot study with blood from
normal individuals. Mixed lymphocyte reaction (MLR) was assayed
using a pool of allogeneic PBMC prepared from 20 different indi-
viduals as described (Bromelow et al, 2001). Intracellular cytokine
assays (IL-2, IL-4, g-INF and TNF-a) were performed as described
for both T cells (Jason and Larned, 1997) and NK cells (Mendes et
al, 2000).
Ethical considerations
The study was approved by the Research Ethics Committee at the
Royal Marsden Hospital, Sutton, UK, and written informed
consent was obtained from all patients.
RESULTS
Recruitment analysis
In total, 16 patients were recruited, mean age 62 years, range 53–
73 years; 12 males, four females. Epithelial mesothelioma was the
most common histological subgroup and 13 patients had a residual
pleural effusion prior to chemotherapy, six of these patients had
had a talc pleurodesis (Table 1). The haematological parameters
of a raised white cell count, raised platelet count and low haema-
globin are included to describe the group as these are known poor
prognostic factors and were present in up to 50% of this study
group. Three patients had previously received cisplatin based
chemotherapy. Table 2 shows the patient numbers with the doses
of intrapleural vaccine received and their overall responses to the
treatment. The protocol recommended three patients to be tested
in each cohort to make up 12 patients in total. However, four
additional patients were recruited in this phase I study as per
protocol to replace speciﬁc patients for the following reasons: three
patients died within the ﬁrst 3 weeks of the study, one from a
myocardial infarction (cohort 3) and two patients (both from
cohort 4) died of progressive disease. An extra patient was
recruited to replace one patient (cohort 4), whose IP dose was
reduced due to fever.
In total, 16 patients entered the trial, of which 13 patients were
assessable for toxicity (two early deaths and one loss to follow-up
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courses given was 3.5; 6 patients received six courses, two patients
four courses, ﬁve patients three courses and the others 4two
courses.
Toxicity
All toxicity was recorded and graded according to the CTC toxicity
guidelines every 3 weeks after chemotherapy. The main side effects
were nausea and vomiting, constipation and hair loss but these
were not severe. The incidence and grade of haematological toxicity
was acceptable (Table 3). Five patients developed pain at the site of
the ID SRL172 injection which was grade 1 and did not require
treatment. Two patients reported grade 2 ﬂu-like symptoms which
resolved over 24 h, one of whom was admitted for observation.
One of these patients had repeated fever with the intrapleural injec-
tions and thus the dose of intrapleural SRL172 was reduced with
no further fever at the lower dose.
Objective and symptomatic responses and survival
Overall, nine out of 16 patients (56%) reported symptomatic bene-
ﬁt from the treatment (Table 4). Of the 14 patients with pain as a
symptom, 10 patients reported improvement, and of the nine
patients with cough, seven patients also described improvement.
The most difﬁcult symptom to treat in this series was dyspnoea
with a response rate of 6 out of 13. Figure 1 illustrates the objective
responses in one of the patients. Overall, there were six out of 16
partial responses (37.5%). For the ﬁrst three cohorts there were
responses in six out of nine assessable patients (one early death)
including a PR in one patient who had been previously treated
and responded to cisplatin. There was a MR in a second previously
treated patient in cohort 4. There was no PD documented in the
ﬁrst two cohorts. There were more objective responses at the lower
doses than at the higher doses (Table 2). The median overall survi-
val was 10.5 months and disease free progression was 8 months
(Figure 2).
Immunological studies
All haemato-immunological parameters tested were compared pre-
and post-treatment with the view to correlating speciﬁc biological
parameters with either response or treatment. Only one haemato-
logical parameter correlated with response; the platelet count
decreased with treatment but the number of patients was too small
to allow meaningful statistical analysis. When the immunological
parameters were analyzed, there was no statistical difference pre-
and post treatment for all types of lymphocytes proliferation (mito-
genic, recall antigen and allogeneic stimulation), the T cell markers
as well as for the production of cytokines by T cells and NK cells
(data not shown). Only two parameters changed statistically with
treatment in all patients tested; there was a signiﬁcant increase in
the percentage of NK cell activated as assessed by expression of
CD69 on NK cells (CD3-CD56+ve gated lymphocytes) (Figure
3); the mean value was 3.8%, standard deviation (s.d.+2.3) pre-
treatment, and 13.7% (s.d.+10%) after treatment (paired t-test
P=0.02, 2-tailed P value). The second observation was a decrease
in the percentage of CD3+ T lymphocytes producing IL-4 after
C
l
i
n
i
c
a
l
Table 1 Patient characteristics at start of treatment (n=16)
Age at diagnosis: median (range) 63 years (53–73)
Male 12
Female 4
Stage IV 16
Pathology
Epithelial 10
Sarcomatoid 0
Mixed 4
Not speciﬁed 2
Pleural effusion
Yes 13
No 3
WHO Performance status
00
11 4
22
Haemaglobin
Males 513 g dl
71 6
Females 511.5 g dl
71 2
White cell count
411610
9 l
71 3
Platelets
4400610
9 l
71 6
Table 2 Patients and treatment
Number of patients Objective responses
Cohort one
10
6 bacilli ml
71 IP 3 PR, NC, PR*
Cohort two
10
7 bacilli ml
71 IP 3 NC*, PR, PR
Cohort three
10
8 bacilli ml
71 IP 4 NE, PR, PD, PR
Cohort four
10
9 bacilli ml
71 6 MR*, PD, PD, NC, NC, NC
PR=partial response; PD=progressive disease; MR=minor response; NC=no change;
NE=not evaluable. *Previously treated with cisplatin.
Table 3 Toxicity – no, of patients (worse grade over all courses – no
grade 4 documented)
Grade 1 Grade 2 Grade 3
Infection 0 2 2
Emesis 5 2 2
Mucositis 2 1 0
Diarrhoea 1 0 0
Constipation 5 0 1
Alopecia 4 3 1
Neuropathy 1 1 0
Fatigue 2 0 0
Altered taste 2 2 0
Haematological
Anaemia 0 8 5
Leucopenia 8 3 1
Thrombocytopenia 11 1 1
Table 4 Symptomatic responses (n=16)
Overall %
SCR SPR SNC SPD NE (CR+PR)
Malaise 1 4 2 0 1 63
Pain 4 6 0 3 1 71
Cough 1 6 1 1 0 78
Dyspnoea 0 6 2 4 1 46
Other symptoms 0 5 3 0 1 56
Overall 0 9 2 3 2* 56
*One mixed. SCR=complete resolution of symptom; SPR=improvement in symp-
tom; SNC=no change in symptom; SPD=symptom worse; NE=not evaluable.
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treatment, and 4.9% (s.d.+1.8%) after treatment (paired t-test
P=0.02, 2-tailed P value).
DISCUSSION
The patients selected for this study all had stage IV mesothelioma
and symptoms from their disease were considered to be either a
similar or worse group to our original report in which a response
rate of 20% was obtained in a group of 39 chemotherapy naı ¨ve
patients (Middleton et al, 1998). The median survival of the earlier
group of patients was 6 months compared to 10.5 months in the
current series which also included three patients who had
previously received cisplatin based chemotherapy. Most of our
patients were male, half of our patients had a low haemoglobin
and six out of 16 had a raised platelet count. Of the other known
prognostic factors most of our patients had the better prognostic
epithelial histological subgroup, were of reasonable performance
status (WHO 1) and only three had a high white cell count
(Curran et al, 1998; Herndon et al, 1998; Edwards et al, 2000).
The good symptomatic response was as previously reported for
the common symptoms with the exception of an improvement in
‘malaise’ – 39% response in the previous series and 63% in the
current series – despite the omission of dexamethasone as an
anti-emetic in most cases with chemotherapy. The higher than
expected number of partial responses seen (six out of nine) in
the ﬁrst three cohorts of this study, with toxicity similar to that
seen with chemotherapy suggests that there may be an advantage
to the addition of local treatment to systemic treatment in the
management of this disease.
We found that most patients after chemotherapy had a
decrease in platelet count, however ﬁve out of six of the patients
who had a documented PR by either WHO or RECIST criteria
had at least a 30% decrease in the platelet count 1 month after
their ﬁnal chemotherapy compared to none out of three of
patients with PD. The numbers are small and therefore the plate-
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Figure 1 Pre- and post-treatment CT scan of responding patient.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 336–341let count has to be formally evaluated in future large studies as a
marker of this nature would have great practical implications in
the assessment of response to treatment in this disease in which
CT scan assessment is both difﬁcult and resource intensive. Inter-
leukin 6 has been implicated as one of the possible soluble factors
responsible for the increase in platelet count seen in mesothelioma
patients (Nakano et al, 1998). It is possible that treatment
decreases interleukin 6 produced by the mesothelioma with a
resulting decrease in the platelet count. As previously shown, high
initial platelet load is an adverse prognostic factor in this disease
(Herndon et al, 1998).
Combinations of chemotherapy and immunotherapy are not
new in the treatment of mesothelioma. Cisplatin used with subcu-
taneous a-interferon at two different doses (3610
6 IU and
6610
6 IU) gave a response rate of 40 and 27% in 26 and 30
patients respectively but with signiﬁcant haematological and non-
haematological toxicity (Soulie et al, 1996; Trandaﬁr et al, 1997).
A reduced dose of cisplatin with mitomycin-C and a-interferon
gave a response rate of 21% in 24 patients (Rodier et al, 1996).
The immunological testing in this study was essentially to screen
different immunological parameters which may have been modiﬁed
by the treatment and could in future studies lead to clariﬁcation of
the mechanisms of action of the regimen. At this stage, we only
included immunological parameters of T cell immunity (both
Th1 and Th2 arms) and parameters of adaptive immunity (NK
cells) following on from the hypothesis that SRL172 could be a
non-speciﬁc immune modulator. SRL172 has been reported to
increase interleulin 2 (IL-2) production in peripheral blood mono-
cytes in patients with melanoma (Maraveyas et al, 1999) and we
had also demonstrated that it leads to NK activation in vitro
(KV Bromelow et al, in preparation). The immunological testing
was only performed in the peripheral blood and future studies
looking at possible immunological changes in the tumour are
warranted. Local stimulation in itself may have a role in the treat-
ment of malignant mesothelioma as in general this disease is
localized for most of its history. We were unable to demonstrate
increased IL-2 production by peripheral T cells (Th1) in this popu-
lation of patients following treatment but local (intratumoural)
production of cytokines is a possibility which should be tested in
the future. IL-2 has been given into the pleura of patients with
mesothelioma with some activity (Eggermont et al, 1991). The
responses were seen at the lower dose level and IL-2 and tumour
necrosis factor were not detectable in the serum. On the other
hand, a signiﬁcant decrease in the proportion of IL-4 producing
CD3
+ T cells (Th2) as well as an increase in NK activation was
recorded in the peripheral blood after SRL172 and chemotherapy
irrespective of the clinical response. At this stage we cannot say
if these measurable biological modiﬁcations are due to SRL172,
chemotherapy or both. However, these changes may have some
direct correlation with response as it is possible that only a propor-
tion of tumours are susceptible, for example, to NK cells (in the
same way only a proportion of patients respond to chemotherapy
despite all receiving the chemotherapy). Therefore possible tumour
inﬁltration by NK cells and cytokine-producing CD3
+ cells need to
be studied in patients with mesothelioma who receive the regimen
tested in this study.
The past 10 years have seen the arrival of a number of new
drugs for the treatment of a number of solid tumours and in parti-
cular non-small cell lung cancer. Many of these new agents have
now been tested in the treatment of mesothelioma both as single
agents and in combination with cisplatin with different response
rates (RR), e.g. Vinorelbine as single agent gave 24% RR in 29
patients (Steele et al, 2000), paclitaxel with cisplatin gave 6% RR
in 18 patients (Caliandro et al, 2000) and gemcitabine and cisplatin
gave 47% RR in 21 patients (Byrne et al, 1999). The survival curves
in this study are very similar to our own study. Another promising
drug is oxaliplatin (Ducreux et al, 1998) which, when combined
with raltitrexed, gave a RR of 41% in 17 patients and was well
tolerated as an out-patient regimen (Fizazi et al, 2000). The activity
of single agent raltitrexed is under investigation by the EORTC and
the antimetabolite MTA (multitargeted antifolate), which also gave
encouraging results in the phase I study (Thodtmann et al, 1999),
is currently in phase III testing. There are also some promising
phase II data using docetaxel which gave a 23% RR in a group
of 22 patients when given at a dose of 100 mg m
72 (Vorobiof et
al, 2000).
Thus for the ﬁrst time we are faced with a number of potentially
active palliative treatments for mesothelioma but the best choice
and the integration of these treatments into current management
strategies awaits the initiation and completion of phase III studies.
We feel the results from the study show that giving doses of
SRL172 at 10
7 bacilli per 0.1 ml dose (1 mg) IP is safe and thus
this should be the dose used for phase II/III studies.
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